Biotechnology
argenx's $2.2 billion acquisition of Forte Biosciences is more than an immunology M&A deal. It is a strategic bet on CD122 biology and a mechanism that targets the T-cell and NK-cell axis in ways the company's existing portfolio does not.
Pharmaceuticals
Eli Lilly's positive Phase 3 results for retatrutide show 22.6% average weight loss in patients with severe obesity and cardiovascular disease—a level historically associated with bariatric surgery. What the data mean for the future of obesity medicine.
Pharmaceuticals
The FDA's approval of Lytenava formalizes what retina specialists have done off-label for over 20 years. The regulatory hurdle is cleared. The commercial one may prove harder.
Pharmaceuticals
Centanafadine's FDA decision on July 24, 2026 marks a potential breakthrough in ADHD treatment. As the first triple monoamine reuptake inhibitor, it could offer a new option for patients who cannot tolerate stimulants.
Biotechnology
GSK's FDA approval of Jideytro marks more than a drug launch—it signals the arrival of second-generation targeted therapies in oncology with meaningful clinical advantages over first-generation inhibitors.
Biotechnology
Agios Pharmaceuticals discontinues tebapivat in sickle cell disease after Phase 2 data fails to show meaningful differentiation from competitors, removing the company's backup narrative and concentrating risk on mitapivat's November FDA decision.
Policy
The FDA's finalized guidance on psychedelic drug development provides the clearest regulatory roadmap yet for companies developing psilocybin, MDMA, and related compounds as treatments for psychiatric disorders.
Biotechnology
Samsung Biologics' $1.81 billion bid for Swiss peptide manufacturer PolyPeptide Group is not just an M&A story. It is a strategic play for control of the GLP-1 drug supply chain, and a signal of where the CDMO industry is heading.
Pharmaceuticals
Merck's enlicitide becomes the first oral PCSK9 inhibitor approved by the FDA, potentially transforming cholesterol treatment by eliminating the need for injections.
Biotechnology
How a drug rescued from Pfizer's shelf became Revtorpyk, the first medicine to simultaneously block all major components of the PI3K/AKT/mTOR pathway in breast cancer—and what it means for oncology's future.
Biotechnology
Biogen's tau-targeting drug BIIB080 demonstrates a 26% slowing of cognitive decline, matching approved Alzheimer's therapies and potentially validating an entirely new treatment category for the disease.
Biotechnology
GSK and Hansoh's ris-rez became the first B7-H3-targeted ADC to demonstrate an overall survival benefit in a Phase 3 trial. Here is what the ARTEMIS-008 result means for small-cell lung cancer patients, the ADC field, and GSK's oncology ambitions.